Role of Helicobacter pylori in gastric mucosa-associated lymphoid tissue lymphomas

World Journal of Gastroenterology

Volumn 20, Issue 3, 2014, Pages 684-698

  Pereira, Marta Isabel ^a,b   Medeiros, José Augusto ^b  

^a CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

Eradication therapy; Gastric lymphoma; Helicobacter pylori; Marginal zone lymphoma; Mucosa associated lymphoid tissue lymphoma; Nuclear factorkappa B pathway

Indexed keywords

B LYMPHOCYTE RECEPTOR; BORTEZOMIB; CD19 ANTIGEN; CD20 ANTIBODY; CD20 ANTIGEN; CD22 ANTIGEN; CD23 ANTIGEN; CD5 ANTIGEN; CD79A ANTIGEN; CLADRIBINE; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CYCLIN D1; CYCLOPHOSPHAMIDE; FLUDARABINE; GEMCITABINE; IBRITUMOMAB TIUXETAN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PREDNISOLONE; RITUXIMAB; THALIDOMIDE; TRANSCRIPTION FACTOR FOXP3; VINCRISTINE;

ANTIBIOTIC THERAPY; ARTICLE; BIOPSY; CANCER PROGNOSIS; CANCER STAGING; CARCINOGENICITY; CD25+ T LYMPHOCYTE; CHROMOSOME ABERRATION; CHROMOSOME TRANSLOCATION; COLONOSCOPY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL (TOPIC); DISEASE COURSE; ENDOSCOPIC ECHOGRAPHY; ESOPHAGOGASTRODUODENOSCOPY; GENE DELETION; GENE REARRANGEMENT; HELICOBACTER PYLORI; HELPER CELL; HISTOPATHOLOGY; HUMAN; IMMUNOGLOBULIN HEAVY CHAIN GENE; IMMUNOGLOBULIN LIGHT CHAIN GENE; IMMUNOHISTOCHEMISTRY; IMMUNOSTIMULATION; MARGINAL ZONE LYMPHOMA; NONHUMAN; PATHOGEN CLEARANCE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POINT MUTATION; PUSH ENTEROSCOPY; RADIOIMMUNOTHERAPY; SIGNAL TRANSDUCTION; STOMACH MUCOSA; TUMOR GROWTH; TUMOR MICROENVIRONMENT;

ERADICATION THERAPY; GASTRIC LYMPHOMA; HELICOBACTER PYLORI; MARGINAL ZONE LYMPHOMA; MUCOSA-ASSOCIATED LYMPHOID TISSUE LYMPHOMA; NUCLEAR FACTOR-KAPPA B PATHWAY;

GASTRIC MUCOSA; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; IMMUNITY, MUCOSAL; LYMPHOMA, B-CELL, MARGINAL ZONE; PROGNOSIS; RISK FACTORS; STOMACH NEOPLASMS;

EID: 84892879891     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i3.684     Document Type: Article

References (131)

1. Isaacson P, Wright DH. Malignant lymphoma of mucosaassociated lymphoid tissue. A distinctive type of B-cell lymphoma. Cancer 1983; 52: 1410-1416 [PMID: 6193858 DOI: 10.1002/1097-0142(19831015)52::8<1410::AIDCNCR2820520813> 3.0.CO;2-3]
2. Isaacson P, Wright DH. Extranodal malignant lymphoma arising from mucosa-associated lymphoid tissue. Cancer 1984; 53: 2515-2524 [PMID: 6424928]
3. Sagaert X, Van Cutsem E, De Hertogh G, Geboes K, Tousseyn T. Gastric MALT lymphoma: a model of chronic inflammation-induced tumor development. Nat Rev Gastroenterol Hepatol 2010; 7: 336-346 [PMID: 20440281 DOI: 10.1038/nrgastro.2010.58]
4. Owens SR, Smith LB. Molecular Aspects of H. pylori-Related MALT Lymphoma. Patholog Res Int 2011; 2011: 193149 [PMID: 21318155]
5. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: International Agency for Research on Cancer (IARC); 2008. Available from: URL: http://apps.who.int/ bookorders/anglais/detart1.jsp?codlan=1&codcol=70&codc ch=4002
6. Powell LD, Baum LG. Overview and compartmentalization of the immune system. In: Hoffman R, Furie B, McGlave P, Silberstein LE, Shattil SJ, Benz EJ, Heslop H. Hematology: Basic Principles and Practice. Oxford, UK: Churchill Livingstone, 2008
7. Orciuolo E, Buda G, Sordi E, Baraté C, Galimberti S, Ciancia E, Petrini M. 2CdA chemotherapy and rituximab in the treatment of marginal zone lymphoma. Leuk Res 2010; 34: 184-189 [PMID: 19414190 DOI: 10.1016/j.leukres.2009.04.003]
8. Troch M, Jonak C, Müllauer L, Püspök A, Formanek M, Hauff W, Zielinski CC, Chott A, Raderer M. A phase II study of bortezomib in patients with MALT lymphoma. Haematologica 2009; 94: 738-742 [PMID: 19336742 DOI: 10.3324/haematol. 2008.001537]
9. Kim do Y, Kim YS, Huh HJ, Choi JS, Yeo JS, Kwak BS, Chae SL. A case of monoclonal gammopathy in extranodal marginal zone B-cell lymphoma of the small intestine. Korean J Lab Med 2011; 31: 18-21 [PMID: 21239866 DOI: 10.3343/ kjlm.2011.31.1.18]
10. Isaacson PG. Update on MALT lymphomas. Best Pract Res Clin Haematol 2005; 18: 57-68 [PMID: 15694184 DOI: 10.1016/ j.beha.2004.08.003]
11. Craig VJ, Cogliatti SB, Arnold I, Gerke C, Balandat JE, Wündisch T, Müller A. B-cell receptor signaling and CD40 ligandindependent T cell help cooperate in Helicobacter-induced MALT lymphomagenesis. Leukemia 2010; 24: 1186-1196 [PMID: 20428202 DOI: 10.1038/leu.2010.76]
12. Konoplev S, Lin P, Qiu X, Medeiros LJ, Yin CC. Clonal relationship of extranodal marginal zone lymphomas of mucosa-associated lymphoid tissue involving different sites. Am J Clin Pathol 2010; 134: 112-118 [PMID: 20551275 DOI: 10.1309/AJCP0HT6ZGSZKNFT]
13. Craig VJ, Arnold I, Gerke C, Huynh MQ, Wündisch T, Neubauer A, Renner C, Falkow S, Müller A. Gastric MALT lymphoma B cells express polyreactive, somatically mutated immunoglobulins. Blood 2010; 115: 581-591 [PMID: 19965661 DOI: 10.1182/blood-2009-06-228015]
14. Hoogeboom R, Bende RJ, van Noesel CJ. MALT lymphomaderived rheumatoid factors are nonpolyreactive high-affinity antibodies. Blood 2010; 116: 1818-1819; author reply 1819-1820 [PMID: 20829382 DOI: 10.1182/blood-2010-03-274613]
15. García M, Bellosillo B, Sánchez-González B, García-Payarols F, Seoane A, Ferrer AM, Gimeno E, Barranco LE, Torner A, Solé F, Besses C, Serrano S, Salar A. Study of regulatory T-cells in patients with gastric malt lymphoma: influence on treatment response and outcome. PLoS One 2012; 7: e51681 [PMID: 23284739 DOI: 10.1371/journal.pone.0051681]
16. Bergman MP, D'Elios MM. Cytotoxic T cells in H. pylori-related gastric autoimmunity and gastric lymphoma. J Biomed Biotechnol 2010; 2010: 104918 [PMID: 20617132]
17. Mégraud F. Helicobacter pylori infection: Review and practice. Presse Med 2010; 39: 815-822 [PMID: 20627443 DOI: 10.1016/j.lpm.2010.04.004]
18. Eck M, Fischbach W. Gastric MALT-type lymphoma. Pathology, pathogenesis, diagnostics and therapy. Pathologe 2010; 31: 188-194 [PMID: 20349062 DOI: 10.1007/ s00292-009-1269-2]
19. Bhandari A, Crowe SE. Helicobacter pylori in gastric malignancies. Curr Gastroenterol Rep 2012; 14: 489-496 [PMID: 23054813 DOI: 10.1007/s11894-012-0296-y]
20. Siddiqui ST, Naz E, Danish F, Mirza T, Aziz S, Ali A. Frequency of Helicobacter pylori in biopsy proven gastritis and its association with lymphoid follicle formation. J Pak Med Assoc 2011; 61: 138-141 [PMID: 21375161]
21. Pervez S, Ali N, Aaqil H, Mumtaz K, Siddiq Ullah S, Akhtar N. Gastric MALT lymphoma: a rarity. J Coll Physicians Surg Pak 2011; 21: 171-172 [PMID: 21419026]
22. Wotherspoon AC, Ortiz-Hidalgo C, Falzon MR, Isaacson PG. Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma. Lancet 1991; 338: 1175-1176 [PMID: 1682595 DOI: 10.1016/0140-6736(91)92035-Z]
23. Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med 2002; 347: 1175-1186 [PMID: 12374879 DOI: 10.1056/NEJMra020542]
24. Nakamura S, Aoyagi K, Furuse M, Suekane H, Matsumoto T, Yao T, Sakai Y, Fuchigami T, Yamamoto I, Tsuneyoshi M, Fujishima M. B-cell monoclonality precedes the development of gastric MALT lymphoma in Helicobacter pyloriassociated chronic gastritis. Am J Pathol 1998; 152: 1271-1279 [PMID: 9588895]
25. Kang SY, Han JH, Ahn MS, Lee HW, Jeong SH, Park JS, Cho YK, Han SU, Kim YB, Kim JH, Sheen SS, Lim HY, Choi JH. Helicobacter pylori infection as an independent prognostic factor for locally advanced gastric cancer patients treated with adjuvant chemotherapy after curative resection. Int J Cancer 2012; 130: 948-958 [PMID: 21425257 DOI: 10.1002/ ijc.26081]
26. Hussell T, Isaacson PG, Crabtree JE, Spencer J. Helicobacter pylori-specific tumour-infiltrating T cells provide contact dependent help for the growth of malignant B cells in low-grade gastric lymphoma of mucosa-associated lymphoid tissue. J Pathol 1996; 178: 122-127 [PMID: 8683376 DOI: 10.1002/(SICI)1096-9896(199602)178::2<122::AIDPATH486> 3.0.CO;2-D]
27. de Boer JP, Raderer M, van Tinteren H, Aleman BM, Boot H, de Jong D. Treatment of extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue with fludarabine: effect on tumor microenvironment. Leuk Lymphoma 2011; 52: 2262-2269 [PMID: 21848361 DOI: 10.3109/10428194.2011.607 527]
28. Hatakeyama M, Higashi H. Helicobacter pylori CagA: a new paradigm for bacterial carcinogenesis. Cancer Sci 2005; 96: 835-843 [PMID: 16367902 DOI: 10.1111/j.1349-7006.2005.00130. x]
29. Li SP, Chen XJ, Sun AH, Zhao JF, Yan J. CagA(+) H. pylori induces Akt1 phosphorylation and inhibits transcription of p21(WAF1/CIP1) and p27(KIP1) via PI3K/Akt1 pathway. Biomed Environ Sci 2010; 23: 273-278 [PMID: 20934114 DOI: 10.1016/S0895-3988(10)60063-3]
30. Nitta H, Zhang W, Kelly BD, Miller M, Pestic-Dragovich L, Bieniarz C, Vasicek TJ, Marafioti T, Rimsza L, Grogan TM. Automated brightfield break-apart in situ hybridization (ba-ISH) application: ALK and MALT1 genes as models. Methods 2010; 52: 352-358 [PMID: 20621192 DOI: 10.1016/ j.ymeth.2010.07.005]
31. Du MQ. MALT lymphoma: many roads lead to nuclear factor-κb activation. Histopathology 2011; 58: 26-38 [PMID: 21261681 DOI: 10.1111/j.1365-2559.2010.03699.x]
32. González D, van der Burg M, García-Sanz R, Fenton JA, Langerak AW, González M, van Dongen JJ, San Miguel JF, Morgan GJ. Immunoglobulin gene rearrangements and the pathogenesis of multiple myeloma. Blood 2007; 110: 3112-3121 [PMID: 17634408 DOI: 10.1182/blood-2007-02-069625]
33. Rosebeck S, Madden L, Jin X, Gu S, Apel IJ, Appert A, Hamoudi RA, Noels H, Sagaert X, Van Loo P, Baens M, Du MQ, Lucas PC, McAllister-Lucas LM. Cleavage of NIK by the API2-MALT1 fusion oncoprotein leads to noncanonical NF-kappaB activation. Science 2011; 331: 468-472 [PMID: 21273489 DOI: 10.1126/science.1198946]
34. Nishikori M. Classical and alternative NF-kB activation pathways and their roles in lymphoid malignancies. J Clin Exp Hematopathol 2005; 45: 15-24 [DOI: 10.3960/jslrt.45.15]
35. Kuo SH, Cheng AL, Lin CW, Hsu CH, Wu MS, Yeh KH, Tzeng YS, Chen LT. t(11; 18)(q21; q21) translocation as predictive marker for non-responsiveness to salvage thalidomide therapy in patients with marginal zone B-cell lymphoma with gastric involvement. Cancer Chemother Pharmacol 2011; 68: 1387-1395 [PMID: 21465313 DOI: 10.1007/s00280-011-1631-y]
36. Dong G, Liu C, Ye H, Gong L, Zheng J, Li M, Huang X, Huang X, Huang Y, Shi Y, Yin W, Gao Z. BCL10 nuclear expression and t(11; 18)(q21; q21) indicate nonresponsiveness to Helicobacter pylori eradication of Chinese primary gastric MALT lymphoma. Int J Hematol 2008; 88: 516-523 [PMID: 18949449 DOI: 10.1007/s12185-008-0187-z]
37. McAllister-Lucas LM, Baens M, Lucas PC. MALT1 protease: a new therapeutic target in B lymphoma and beyond? Clin Cancer Res 2011; 17: 6623-6631 [PMID: 21868762 DOI: 10.1158/1078-0432.CCR-11-0467]
38. Nakagawa M, Hosokawa Y, Yonezumi M, Izumiyama K, Suzuki R, Tsuzuki S, Asaka M, Seto M. MALT1 contains nuclear export signals and regulates cytoplasmic localization of BCL10. Blood 2005; 106: 4210-4216 [PMID: 16123224 DOI: 10.1182/blood-2004-12-4785]
39. Hamoudi RA, Appert A, Ye H, Ruskone-Fourmestraux A, Streubel B, Chott A, Raderer M, Gong L, Wlodarska I, De Wolf-Peeters C, MacLennan KA, de Leval L, Isaacson PG, Du MQ. Differential expression of NF-kappaB target genes in MALT lymphoma with and without chromosome translocation: insights into molecular mechanism. Leukemia 2010; 24: 1487-1497 [PMID: 20520640 DOI: 10.1038/leu.2010.118]
40. Bende RJ, Aarts WM, Riedl RG, de Jong D, Pals ST, van Noesel CJ. Among B cell non-Hodgkin's lymphomas, MALT lymphomas express a unique antibody repertoire with frequent rheumatoid factor reactivity. J Exp Med 2005; 201: 1229-1241 [PMID: 15837810 DOI: 10.1084/jem.20050068]
41. Nakamura S, Matsumoto T, Nakamura S, Jo Y, Fujisawa K, Suekane H, Yao T, Tsuneyoshi M, Iida M. Chromosomal translocation t(11; 18)(q21; q21) in gastrointestinal mucosa associated lymphoid tissue lymphoma. J Clin Pathol 2003; 56: 36-42 [PMID: 12499431 DOI: 10.1136/jcp.56.1.36]
42. Tibiletti MG, Milani K, Martin V, Zucca E, Motta T, Cortelazzo S, Pinotti G, Mazzucchelli L, Pruneri G, Martinelli G, Barbazza R, Capella C, Bertoni F. Chromosome instability and translocation t(11; 18) in primary gastric marginal zone B-cell lymphoma of MALT-type. Hematol Oncol 2007; 25: 184-188 [PMID: 17607663 DOI: 10.1002/hon.825]
43. Maes B, Baens M, Marynen P, De Wolf-Peeters C. The product of the t(11; 18), an API2-MLT fusion, is an almost exclusive finding in marginal zone cell lymphoma of extranodal MALT-type. Ann Oncol 2000; 11: 521-526 [PMID: 10907943 DOI: 10.1023/A:1008357314157]
44. Li BZ, Lu HF, Zhou XY, Yang WT, Kong YY, Fan YZ, Shi DR. Frequency of genetic aberrations in mucosa-associated lymphoid tissue lymphoma of different sites. Zhonghua Binglixue Zazhi 2008; 37: 604-608 [PMID: 19094584]
45. Jaffe ES, Pittaluga S. The pathologic basis for the classification of non-Hodgkin lymphomas. In: Hoffman R, Furie B, McGlave P, Silberstein LE, Shattil SJ, Benz EJ, Heslop H. Hematology: Basic Principles and Practice. Oxford, UK: Churchill Livingstone, 2008
46. Streubel B, Lamprecht A, Dierlamm J, Cerroni L, Stolte M, Ott G, Raderer M, Chott A. T(14; 18)(q32; q21) involving IGH and MALT1 is a frequent chromosomal aberration in MALT lymphoma. Blood 2003; 101: 2335-2339 [PMID: 12406890 DOI: 10.1182/blood-2002-09-2963]
47. Sanchez-Izquierdo D, Buchonnet G, Siebert R, Gascoyne RD, Climent J, Karran L, Marin M, Blesa D, Horsman D, Rosenwald A, Staudt LM, Albertson DG, Du MQ, Ye H, Marynen P, Garcia-Conde J, Pinkel D, Dyer MJ, Martinez-Climent JA. MALT1 is deregulated by both chromosomal translocation and amplification in B-cell non-Hodgkin lymphoma. Blood 2003; 101: 4539-4546 [PMID: 12560219 DOI: 10.1182/blood-2002-10-3236]
48. Streubel B, Vinatzer U, Lamprecht A, Raderer M, Chott A. T(3; 14)(p14.1; q32) involving IGH and FOXP1 is a novel recurrent chromosomal aberration in MALT lymphoma. Leukemia 2005; 19: 652-658 [PMID: 15703784 DOI: 10.1038/ sj.leu.2403644]
49. Sagaert X, de Paepe P, Libbrecht L, Vanhentenrijk V, Verhoef G, Thomas J, Wlodarska I, De Wolf-Peeters C. Forkhead box protein P1 expression in mucosa-associated lymphoid tissue lymphomas predicts poor prognosis and transformation to diffuse large B-cell lymphoma. J Clin Oncol 2006; 24: 2490-2497 [PMID: 16636337 DOI: 10.1200/JCO.2006.05.6150]
50. Zhai L, Zhao Y, Ye S, Huang H, Tian Y, Wu Q, Lin H, Lin T. Expression of PIK3CA and FOXP1 in gastric and intestinal non-Hodgkin's lymphoma of mucosa-associated lymphoid tissue type. Tumour Biol 2011; 32: 913-920 [PMID: 21660567 DOI: 10.1007/s13277-011-0192-3]
51. Craig VJ, Cogliatti SB, Imig J, Renner C, Neuenschwander S, Rehrauer H, Schlapbach R, Dirnhofer S, Tzankov A, Müller A. Myc-mediated repression of microRNA-34a promotes high-grade transformation of B-cell lymphoma by dysregulation of FoxP1. Blood 2011; 117: 6227-6236 [PMID: 21460242 DOI: 10.1182/blood-2010-10-312231]
52. Zhang XM, Zhang WY, Zhou YP, Mo XL, Li YP, Wang GQ, Zhou YQ, Zeng SE, Li GD, Ye HT. Study on genetic aberrations of ocular mucosa-associated lymphoid tissue lymphomas occurring in southern China. Zhonghua Binglixue Zazhi 2010; 39: 513-517 [PMID: 21055028]
53. Remstein ED, Dogan A, Einerson RR, Paternoster SF, Fink SR, Law M, Dewald GW, Kurtin PJ. The incidence and anatomic site specificity of chromosomal translocations in primary extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) in North America. Am J Surg Pathol 2006; 30: 1546-1553 [PMID: 17122510 DOI: 10.1097/01.pas.0000213275.60962.2a]
54. Thieblemont C, Berger F, Dumontet C, Moullet I, Bouafia F, Felman P, Salles G, Coiffier B. Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed. Blood 2000; 95: 802-806 [PMID: 10648389]
55. He S, Guo Y, Bei CF, Dai YZ, Zhu DB, Li CS, Zhu XH, LE MZ. Gastrointestinal B-cell lymphoma: a morphologic and immunohistochemical study of 194 cases. Zhonghua Binglixue Zazhi 2010; 39: 814-818 [PMID: 21215096]
56. Samee A, Rukin N, Siddiqui I, Halliday M, Farmer M. A solitary rectal mucosa-associated lymphoid tissue (MALT) lymphoma. BMJ Case Rep 2010; 2010: pii: bcr0120102649 [PMID: 22767556 DOI: 10.1136/bcr.01.2010.2649]
57. Ersoz F, Toros AB, Bektas H, Ozcan O, Koc O, Arikan S. MALT lymphoma of the rectum, presenting with rectal prolapsus: a case report. Cases J 2010; 3: 33 [PMID: 20180989 DOI: 10.1186/1757-1626-3-33]
58. Aleman BM, Haas RL, van der Maazen RW. Role of radio-therapy in the treatment of lymphomas of the gastrointestinal tract. Best Pract Res Clin Gastroenterol 2010; 24: 27-34 [PMID: 20206106 DOI: 10.1016/j.bpg.2009.12.002]
59. Dolak W, Raderer M, Maresch J, Muellauer L, Puespoek A, Chott A, Haefner M. Detection of gastric MALT lymphoma spreading to the small bowel by enteroscopy. Endoscopy 2011; 43: 731-733 [PMID: 21656457 DOI: 10.1055/s-0030-1256435]
60. Matsuo T, Ichimura K, Okada H, Shinagawa K, Fukushima K, Okano M, Otsuka M, Yoshino T. Clonal analysis of bilateral, recurrent, or systemically multifocal ocular adnexal lymphoma. J Clin Exp Hematop 2010; 50: 27-38 [PMID: 20505273 DOI: 10.3960/jslrt.50.27]
61. Devi P, Pattanayak L, Samantaray S. Synchronous adenocarcinoma and mucosa-associated lymphoid tissue lymphoma of the colon. Saudi J Gastroenterol 2011; 17: 69-71 [PMID: 21196657 DOI: 10.4103/1319-3767.74455]
62. Akiba J, Nakane T, Arakawa F, Ohshima K, Yano H. Collision of EBV-associated gastric carcinoma and primary gastric extranodal marginal zone lymphoma of mucosaassociated lymphoid tissue in the remnant stomach. Pathol Int 2010; 60: 102-106 [PMID: 20398194 DOI: 10.1111/ j.1440-1827.2009.02479.x]
63. Terada T. One patient with double lymphomas: simultaneous gastric MALT lymphoma and ileal diffuse large B-cell lymphoma. Int J Clin Exp Pathol 2012; 5: 260-263 [PMID: 22558482]
64. Melo GM, Sguilar DA, Petiti CM, Eichstaedt AG, Caiado RR, Souza RA. Concomitant thyroid Malt lymphoma and papillary thyroid carcinoma. Arq Bras Endocrinol Metabol 2010; 54: 425-428 [PMID: 20625656]
65. Dreyling M, Thieblemont C, Gallamini A, Arcaini L, Campo E, Hermine O, Kluin-Nelemans JC, Ladetto M, Le Gouill S, Iannitto E, Pileri S, Rodriguez J, Schmitz N, Wotherspoon A, Zinzani P, Zucca E. ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma. Ann Oncol 2013; 24: 857-877 [PMID: 23425945 DOI: 10.1093/ annonc/mds643]
66. Borie R, Wislez M, Antoine M, Fleury-Feith J, Thabut G, Crestani B, Monnet I, Nunes H, Delfau-Larue MH, Cadranel J. Clonality and phenotyping analysis of alveolar lymphocytes is suggestive of pulmonary MALT lymphoma. Respir Med 2011; 105: 1231-1237 [PMID: 21481576 DOI: 10.1016/ j.rmed.2011.03.018]
67. Thorns C, Kuba J, Bernard V, Senft A, Szymczak S, Feller AC, Bernd HW. Deregulation of a distinct set of microRNAs is associated with transformation of gastritis into MALT lymphoma. Virchows Arch 2012; 460: 371-377 [PMID: 22395483 DOI: 10.1007/s00428-012-1215-1]
68. Ferrucci PF, Zucca E. Primary gastric lymphoma pathogenesis and treatment: what has changed over the past 10 years? Br J Haematol 2007; 136: 521-538 [PMID: 17156403 DOI: 10.1111/j.1365-2141.2006.06444.x]
69. Li X, Xia B, Guo S, Zhan Z, Zhang L, Zhao D, Wu X, Zhang Y. A retrospective analysis of primary gastric diffuse large B-cell lymphoma with or without concomitant mucosa-associated lymphoid tissue (MALT) lymphoma components. Ann Hematol 2013; 92: 807-815 [PMID: 23417758 DOI: 10.1007/ s00277-013-1701-9]
70. Ishimaru A, Kitsukawa M. Report of a case of perforated giant gastric malignant lymphoma. Gan To Kagaku Ryoho 2011; 38: 663-666 [PMID: 21499001]
71. Ikuta K, Fujiya M, Ueno N, Hosoki T, Moriichi K, Honda M, Torimoto Y, Yamochi T, Ota H, Kohgo Y. Atypical mucosaassociated lymphoid tissue lymphoma in the transverse colon associated with macroglobulinemia. Intern Med 2010; 49: 677-682 [PMID: 20371958 DOI: 10.2169/internalmedicine. 49.3160]
72. Choi JY, Lee GH, Ahn JY, Kim MY, Lee JH, Choi KS, Kim do H, Choi KD, Song HJ, Jung HY, Kim JH. The role of abdominal CT scan as follow-up after complete remission with successful Helicobacter pylori eradication in patients with H. pylori-positive stage I(E1) gastric MALT lymphoma. Helicobacter 2011; 16: 36-41 [PMID: 21241410 DOI: 10.1111/ j.1523-5378.2010.00807.x]
73. Ono S, Kato M, Ono Y, Nishida U, Yamamoto K, Shimizu Y, Asaka M. Target biopsy using magnifying endoscopy in clinical management of gastric mucosa-associated lymphoid tissue lymphoma. J Gastroenterol Hepatol 2011; 26: 1133-1138 [PMID: 21443666 DOI: 10.1111/j.1440-1746.2011.06729.x]
74. Bahn YE, Lee SK, Kwon SY, Kim SP. Sonographic appearances of mucosa-associated lymphoid tissue lymphoma of the submandibular gland confirmed with sonographically guided core needle biopsy. J Clin Ultrasound 2011; 39: 228-232 [PMID: 21480289 DOI: 10.1002/jcu.20754]
75. Kim HJ, Ha HK, Kim HJ, Byeon JS, Kim MJ, Lee SS, Park SH, Kim AY. Gastrointestinal dissemination of mucosa-associated lymphoid tissue lymphoma: computed tomographic findings. J Comput Assist Tomogr 2010; 34: 187-192 [PMID: 20351501 DOI: 10.1097/RCT.0b013e3181bbd21e]
76. Hayashi D, Devenney-Cakir B, Lee JC, Kim SH, Cheng J, Goldfeder S, Choi BI, Guermazi A. Mucosa-associated lymphoid tissue lymphoma: multimodality imaging and histopathologic correlation. AJR Am J Roentgenol 2010; 195: W105-W117 [PMID: 20651169 DOI: 10.2214/AJR.09.4105]
77. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res 1971; 31: 1860-1861 [PMID: 5121694]
78. Lister TA, Crowther D, Sutcliffe SB, Glatstein E, Canellos GP, Young RC, Rosenberg SA, Coltman CA, Tubiana M. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 1989; 7: 1630-1636 [PMID: 2809679]
79. Radaszkiewicz T, Dragosics B, Bauer P. Gastrointestinal malignant lymphomas of the mucosa-associated lymphoid tissue: factors relevant to prognosis. Gastroenterology 1992; 102: 1628-1638 [PMID: 1568573]
80. Rohatiner A, d'Amore F, Coiffier B, Crowther D, Gospodarowicz M, Isaacson P, Lister TA, Norton A, Salem P, Shipp M. Report on a workshop convened to discuss the pathological and staging classifications of gastrointestinal tract lymphoma. Ann Oncol 1994; 5: 397-400 [PMID: 8075046]
81. Ruskoné-Fourmestraux A, Dragosics B, Morgner A, Wotherspoon A, De Jong D. Paris staging system for primary gastrointestinal lymphomas. Gut 2003; 52: 912-913 [PMID: 12740354 DOI: 10.1136/gut.52.6.912]
82. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993; 329: 987-994 [PMID: 8141877 DOI: 10.1056/NEJM199309303291402]
83. Troch M, Wöhrer S, Raderer M. Assessment of the prognostic indices IPI and FLIPI in patients with mucosa-associated lymphoid tissue lymphoma. Anticancer Res 2010; 30: 635-639 [PMID: 20332482]
84. Heilgeist A, McClanahan F, Ho AD, Witzens-Harig M. Prognostic value of the Follicular Lymphoma International Prognostic Index score in marginal zone lymphoma: an analysis of clinical presentation and outcome in 144 patients. Cancer 2013; 119: 99-106 [PMID: 22736411 DOI: 10.1002/cncr.27704]
85. Olszewski AJ, Castillo JJ. Survival of patients with marginal zone lymphoma: analysis of the Surveillance, Epidemiology, and End Results database. Cancer 2013; 119: 629-638 [PMID: 22893605 DOI: 10.1002/cncr.27773]
86. Todorovic M, Balint B, Jevtic M, Suvajdzic N, Ceric A, Stamatovic D, Markovic O, Perunicic M, Marjanovic S, Krstic M. Primary gastric mucosa associated lymphoid tissue lymphoma: clinical data predicted treatment outcome. World J Gastroenterol 2008; 14: 2388-2393 [PMID: 18416467 DOI: 10.3748/wjg.14.2388]
87. Flossbach L, Antoneag E, Buck M, Siebert R, Mattfeldt T, Möller P, Barth TF. BCL6 gene rearrangement and protein expression are associated with large cell presentation of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. Int J Cancer 2011; 129: 70-77 [PMID: 20830719 DOI: 10.1002/ijc.25663]
88. Chen YW, Hu XT, Liang AC, Au WY, So CC, Wong ML, Shen L, Tao Q, Chu KM, Kwong YL, Liang RH, Srivastava G. High BCL6 expression predicts better prognosis, independent of BCL6 translocation status, translocation partner, or BCL6-deregulating mutations, in gastric lymphoma. Blood 2006; 108: 2373-2383 [PMID: 16772602 DOI: 10.1182/ blood-2006-05-022517]
89. Ruskoné-Fourmestraux A, Fischbach W, Aleman BM, Boot H, Du MQ, Megraud F, Montalban C, Raderer M, Savio A, Wotherspoon A. EGILS consensus report. Gastric extranodal marginal zone B-cell lymphoma of MALT. Gut 2011; 60: 747-758 [PMID: 21317175 DOI: 10.1136/gut.2010.224949]
90. Oh SY, Kim WS, Lee DH, Kim SJ, Kim SH, Ryoo BY, Kang HJ, Choi YJ, Chung JS, Kim HJ, Suh C. Phase II study of gemcitabine for treatment of patients with advanced stage marginal zone B-cell lymphoma: Consortium for Improving Survival of Lymphoma (CISL) trial. Invest New Drugs 2010; 28: 171-177 [PMID: 19421710 DOI: 10.1007/s10637-009-9260-6]
91. Kirschbaum M, Frankel P, Popplewell L, Zain J, Delioukina M, Pullarkat V, Matsuoka D, Pulone B, Rotter AJ, Espinoza-Delgado I, Nademanee A, Forman SJ, Gandara D, Newman E. Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 2011; 29: 1198-1203 [PMID: 21300924 DOI: 10.1200/JCO.2010.32.1398]
92. Nakamura S, Sugiyama T, Matsumoto T, Iijima K, Ono S, Tajika M, Tari A, Kitadai Y, Matsumoto H, Nagaya T, Kamoshida T, Watanabe N, Chiba T, Origasa H, Asaka M. Long-term clinical outcome of gastric MALT lymphoma after eradication of Helicobacter pylori: a multicentre cohort follow-up study of 420 patients in Japan. Gut 2012; 61: 507-513 [PMID: 21890816 DOI: 10.1136/gutjnl-2011-300495]
93. Sato C, Suzuki H, Watanabe M, Kojima K, Tsuchida F, Takeda H. Spontaneous regression of mucosa-associated lymphoid tissue lymphoma of the lung. Nihon Kokyuki Gakkai Zasshi 2010; 48: 677-682 [PMID: 20954370]
94. Makino Y, Suzuki H, Nishizawa T, Kameyama K, Hisamatsu T, Imaeda H, Mukai M, Hibi T. Ileal Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma with a Large-Cell Component That Regressed Spontaneously. Gut Liver 2010; 4: 117-121 [PMID: 20479924 DOI: 10.5009/gnl.2010.4.1.117]
95. Al Furaikh SS. Remission of high-grade B-cell lymphoma in a pediatric patient following Helicobacter pylori eradication. Pediatr Int 2011; 53: 105-107 [PMID: 21342336 DOI: 10.1111/ j.1442-200X.2010.03142.x]
96. Kuo SH, Yeh KH, Wu MS, Lin CW, Hsu PN, Wang HP, Chen LT, Cheng AL. Helicobacter pylori eradication therapy is effective in the treatment of early-stage H pyloripositive gastric diffuse large B-cell lymphomas. Blood 2012; 119: 4838-4844; quiz 5057 [PMID: 22403257 DOI: 10.1182/ blood-2012-01-404194]
97. Suzuki H, Saito Y, Hibi T. Helicobacter pylori and Gastric Mucosa-associated Lymphoid Tissue (MALT) Lymphoma: Updated Review of Clinical Outcomes and the Molecular Pathogenesis. Gut Liver 2009; 3: 81-87 [PMID: 20431728 DOI: 10.5009/gnl.2009.3.2.81]
98. Fischbach W. Long-term follow-up of gastric lymphoma after stomach conserving treatment. Best Pract Res Clin Gastroenterol 2010; 24: 71-77 [PMID: 20206110 DOI: 10.1016/ j.bpg.2009.12.005]
99. Kim SJ, Yang S, Min BH, Lee JH, Rhee PL, Rhee JC, Kim JJ. Helicobacter pylori eradication for stage I(E1) gastric mucosa-associated lymphoid tissue lymphoma: predictive factors of complete remission. Korean J Gastroenterol 2010; 55: 94-99 [PMID: 20168055 DOI: 10.4166/kjg.2010.55.2.94]
100. Yepes S, Torres MM, Saavedra C, Andrade R. Gastric mucosa-associated lymphoid tissue lymphomas and Helicobacter pylori infection: a Colombian perspective. World J Gastroenterol 2012; 18: 685-691 [PMID: 22363141 DOI: 10.3748/wjg. v18.i7.685]
101. Bytzer P, Dahlerup JF, Eriksen JR, Jarbøl DE, Rosenstock S, Wildt S. Diagnosis and treatment of Helicobacter pylori infection. Dan Med Bull 2011; 58: C4271 [PMID: 21466771]
102. Suhaila N, Hussin S, Rahman MM. Comparative efficacy sensitivity and specificity of the tests used for the Diagnosis of Helicobacter pylori. Pak J Biol Sci 2010; 13: 1057-1061 [PMID: 21313878 DOI: 10.3923/pjbs.2010.1057.1061]
103. Konno T, Motoori S, Iwamoto N, Miyazawa T, Saito S, Kitagawa N, Saisho H, Furuse J, Itabashi M. A case of mucosa-associated lymphoid tissue lymphoma with penicillin allergy successfully treated with levofloxacin, minomycin and rabeprazole. Gan To Kagaku Ryoho 2010; 37: 1961-1964 [PMID: 20948264]
104. Medeiros JA, Gonçalves TM, Boyanova L, Pereira MI, de Carvalho JN, Pereira AM, Cabrita AM. Evaluation of Helicobacter pylori eradication by triple therapy plus Lactobacillus acidophilus compared to triple therapy alone. Eur J Clin Microbiol Infect Dis 2011; 30: 555-559 [PMID: 21207091 DOI: 10.1007/s10096-010-1119-4]
105. Copie-Bergman C, Wotherspoon AC, Capella C, Motta T, Pedrinis E, Pileri SA, Bertoni F, Conconi A, Zucca E, Ponzoni M, Ferreri AJ. Gela histological scoring system for posttreatment biopsies of patients with gastric MALT lymphoma is feasible and reliable in routine practice. Br J Haematol 2013; 160: 47-52 [PMID: 23043300 DOI: 10.1111/bjh.12078]
106. Ono S, Kato M, Takagi K, Kodaira J, Kubota K, Matsuno Y, Komatsu Y, Asaka M. Long-term treatment of localized gastric marginal zone B-cell mucosa associated lymphoid tissue lymphoma including incidence of metachronous gastric cancer. J Gastroenterol Hepatol 2010; 25: 804-809 [PMID: 20492338 DOI: 10.1111/j.1440-1746.2009.06204.x]
107. Fischbach W, Goebeler ME, Ruskone-Fourmestraux A, Wündisch T, Neubauer A, Raderer M, Savio A. Most patients with minimal histological residuals of gastric MALT lymphoma after successful eradication of Helicobacter pylori can be managed safely by a watch and wait strategy: experience from a large international series. Gut 2007; 56: 1685-1687 [PMID: 17639089 DOI: 10.1136/gut.2006.096420]
108. Wündisch T, Dieckhoff P, Greene B, Thiede C, Wilhelm C, Stolte M, Neubauer A. Second cancers and residual disease in patients treated for gastric mucosa-associated lymphoid tissue lymphoma by Helicobacter pylori eradication and followed for 10 years. Gastroenterology 2012; 143: 936-942; quiz e13-e14 [PMID: 22750463 DOI: 10.1053/j.gastro.2012.06.035]
109. Ferreri AJ, Dolcetti R, Du MQ, Doglioni C, Resti AG, Politi LS, De Conciliis C, Radford J, Bertoni F, Zucca E, Cavalli F, Ponzoni M. Ocular adnexal MALT lymphoma: an intriguing model for antigen-driven lymphomagenesis and microbialtargeted therapy. Ann Oncol 2008; 19: 835-846 [PMID: 17986622 DOI: 10.1093/annonc/mdm513]
110. Park HS, Kim YJ, Yang WI, Suh CO, Lee YC. Treatment outcome of localized Helicobacter pylori-negative low-grade gastric MALT lymphoma. World J Gastroenterol 2010; 16: 2158-2162 [PMID: 20440857 DOI: 10.3748/wjg.v16.i17.2158]
111. Asano N, Iijima K, Terai S, Jin X, Ara N, Chiba T, Fushiya J, Koike T, Imatani A, Shimosegawa T. Eradication therapy is effective for Helicobacter pylori-negative gastric mucosa-associated lymphoid tissue lymphoma. Tohoku J Exp Med 2012; 228: 223-227 [PMID: 23076291 DOI: 10.1620/tjem.228.223. Correspondence]
112. Miyazaki T, Ishiguro T, Ishibashi K, Itoyama S, Ishida H. Mucosa-associated lymphoid tissue lymphoma of the appendix vermiformis. Int Surg 2010; 95: 27-32 [PMID: 20480837]
113. Gardini A, Saragoni L, La Barba G, Garcea D. Simultane-ous occurrence of primary diffuse large B-cell lymphoma and extranodal marginal zone (MALT) B-cell lymphoma in the gallbladder: a case report. Pathologica 2009; 101: 230-234 [PMID: 20387709]
114. Deinbeck K, Geinitz H, Haller B, Fakhrian K. Radiotherapy in marginal zone lymphoma. Radiat Oncol 2013; 8: 2 [PMID: 23281682 DOI: 10.1186/1748-717X-8-2]
115. Hancock BW, Qian W, Linch D, Delchier JC, Smith P, Jakupovic I, Burton C, Souhami R, Wotherspoon A, Copie-Bergman C, Capella C, Traulle C, Levy M, Cortelazzo S, Ferreri AJ, Ambrosetti A, Pinotti G, Martinelli G, Vitolo U, Cavalli F, Gisselbrecht C, Zucca E. Chlorambucil versus observation after anti-Helicobacter therapy in gastric MALT lymphomas: results of the international randomised LY03 trial. Br J Haematol 2009; 144: 367-375 [PMID: 19036078 DOI: 10.1111/ j.1365-2141.2008.07486.x]
116. Morgner A, Schmelz R, Thiede C, Stolte M, Miehlke S. Therapy of gastric mucosa associated lymphoid tissue lymphoma. World J Gastroenterol 2007; 13: 3554-3566 [PMID: 17659705]
117. Avilés A, Nambo MJ, Neri N, Talavera A, Cleto S. Mucosaassociated lymphoid tissue (MALT) lymphoma of the stomach: results of a controlled clinical trial. Med Oncol 2005; 22: 57-62 [PMID: 15750197 DOI: 10.1385/MO::22:1:057]
118. Jäger G, Neumeister P, Quehenberger F, Wöhrer S, Linkesch W, Raderer M. Prolonged clinical remission in patients with extranodal marginal zone B-cell lymphoma of the mucosaassociated lymphoid tissue type treated with cladribine: 6 year follow-up of a phase II trial. Ann Oncol 2006; 17: 1722-1723 [PMID: 16766585 DOI: 10.1093/annonc/mdl126]
119. Kahl BS, Bartlett NL, Leonard JP, Chen L, Ganjoo K, Williams ME, Czuczman MS, Robinson KS, Joyce R, van der Jagt RH, Cheson BD. Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study. Cancer 2010; 116: 106-114 [PMID: 19890959 DOI: 10.1002/ cncr.24714]
120. Ben Simon GJ, Cheung N, McKelvie P, Fox R, McNab AA. Oral chlorambucil for extranodal, marginal zone, B-cell lymphoma of mucosa-associated lymphoid tissue of the orbit. Ophthalmology 2006; 113: 1209-1213 [PMID: 16647129 DOI: 10.1016/j.ophtha.2006.01.057]
121. Conconi A, Martinelli G, Lopez-Guillermo A, Zinzani PL, Ferreri AJ, Rigacci L, Devizzi L, Vitolo U, Luminari S, Cavalli F, Zucca E. Clinical activity of bortezomib in relapsed/refractory MALT lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group (IELSG). Ann Oncol 2011; 22: 689-695 [PMID: 20810546 DOI: 10.1093/ annonc/mdq416]
122. Tektonidou MG. MALT lymphoma of the lacrimal gland in the context of systemic lupus erythematosus: complete remission after treatment with rituximab. Lupus 2010; 19: 1243-1245 [PMID: 20501524 DOI: 10.1177/0961203310367659]
123. Shetty RK, Adams BH, Tun HW, Runyan BR, Menke DM, Broderick DF. Use of rituximab for periocular and intraocular mucosa-associated lymphoid tissue lymphoma. Ocul Immunol Inflamm 2010; 18: 110-112 [PMID: 20370339 DOI: 10.3109/09273940903450313]
124. Nakajima T, Yasufuku K, Sekine Y, Yoshida S, Yoshino I. Mucosa-associated lymphoid tissue lymphoma of the left mainstem bronchus. Ann Thorac Surg 2011; 91: 1281-1283 [PMID: 21440165 DOI: 10.1016/j.athoracsur.2010.10.009]
125. Kagawa M, Okamura S, Okamoto K, Kitamura S, Kimura T, Niki M, Kaji M, Okahisa T, Yano M, Kagawa S, Kudo E, Sano T, Imoto Y, Wada S, Takayama T. Successful rituximab monotherapy in a patient with mucosa-associated lymphoid tissue lymphoma of the rectum with trisomy 3, 18. Nihon Shokakibyo Gakkai Zasshi 2010; 107: 612-619 [PMID: 20379095]
126. Kang HJ, Kim WS, Kim SJ, Lee JJ, Yang DH, Kim JS, Lee SR, Lee GW, Kim HJ, Kim HY, Oh SY, Kim HC, Eom HS, Chung J, Park J, Suh C, Ryoo BY. Phase II trial of rituximab plus CVP combination chemotherapy for advanced stage marginal zone lymphoma as a first-line therapy: Consortium for Improving Survival of Lymphoma (CISL) study. Ann Hematol 2012; 91: 543-551 [PMID: 21922208 DOI: 10.1007/ s00277-011-1337-6]
127. Salar A, Domingo-Domenech E, Estany C, Canales MA, Gallardo F, Servitje O, Fraile G, Montalbán C. Combination therapy with rituximab and intravenous or oral fludarabine in the first-line, systemic treatment of patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type. Cancer 2009; 115: 5210-5217 [PMID: 19672998 DOI: 10.1002/cncr.24605]
128. Zucca E, Conconi A, Laszlo D, López-Guillermo A, Bouabdallah R, Coiffier B, Sebban C, Jardin F, Vitolo U, Morschhauser F, Pileri SA, Copie-Bergman C, Campo E, Jack A, Floriani I, Johnson P, Martelli M, Cavalli F, Martinelli G, Thieblemont C. Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 Randomized Study. J Clin Oncol 2013; 31: 565-572 [PMID: 23295789 DOI: 10.1200/ JCO.2011.40.6272]
129. Oh SY, Kim WS, Kim JS, Kim SJ, Lee S, Lee DH, Won JH, Hwang IG, Kim MK, Lee SI, Chae YS, Yang DH, Kang HJ, Choi CW, Park J, Kim HJ, Kwon JH, Lee HS, Lee GW, Eom HS, Kwak JY, Suh C, Kim HJ. Stage IV marginal zone B-cell lymphoma--prognostic factors and the role of rituximab: Consortium for Improving Survival of Lymphoma (CISL) study. Cancer Sci 2010; 101: 2443-2447 [PMID: 20831770 DOI: 10.1111/j.1349-7006.2010.01698.x]
130. Hoffmann M, Troch M, Eidherr H, Traub-Weidinger T, Jonak C, Muellauer L, Raderer M. 90Y-ibritumomab tiuxetan (Zevalin) in heavily pretreated patients with mucosa associated lymphoid tissue lymphoma. Leuk Lymphoma 2011; 52: 42-45 [PMID: 21133720 DOI: 10.3109/10428194.2010.534519]
131. Esmaeli B, McLaughlin P, Pro B, Samaniego F, Gayed I, Hagemeister F, Romaguera J, Cabanillas F, Neelapu SS, Banay R, Fayad L, Wayne Saville M, Kwak LW. Prospective trial of targeted radioimmunotherapy with Y-90 ibritumomab tiuxetan (Zevalin) for front-line treatment of early-stage extranodal indolent ocular adnexal lymphoma. Ann Oncol 2009; 20: 709-714 [PMID: 19150940 DOI: 10.1093/annonc/ mdn692]